Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (2356)	3/19/2018 3:59:24 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

Yes, Dupi prospert is next to Eylea, and as market report here, it is almost as much restriction on Dupi Rx as was/is on Praluent Rx. Can you imagine, so fur there is no single Dupi Rx from pulmonologist, for allergic asthma???? That really describe RESTRICTION on Rx!

To: Biotech Jim who wrote (2356)	3/19/2018 9:59:21 PM
From: Felix B	Respond to of 3559

I've always wondered how much sway these analysts have. Although a majority of REGN shareholders are institutions but surely some of those have their own private analysts.